The link is the enzyme Tankyrase and its pivotal role in switching on or off the protein that controls two known cancer genes. In normal cells, the protein is vital for bone development. In abnormal cells, it is thought to be involved in two common types of blood cancer – chronic myelogenous leukemia and acute myeloid leukemia.
The findings, published online today in CELL (DOI: 10.1016/j.cell.2011.10.046), zero in on how the enzyme alters the protein 3BP2, says principal investigator Dr. Robert Rottapel, clinician-scientist at The Campbell Family Institute for Cancer Research in the Princess Margaret Cancer Program, University Health Network and St. Michael’s Hospital. He is also a Professor, Faculty of Medicine, University of Toronto, and holds the Amgen Chair for Cancer Research.
“We have defined the rules of engagement for Tankyrase, which clearly identifies a potential target for developing therapeutic agents for human disease,” says Dr. Rottapel. These studies point the way for new therapeutic approaches in treating cherubism, using inhibitors that are already available in the clinic.
In a separate but related study (also published today) co-led by Dr. Rottapel and Dr. Frank Sicheri at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, the investigators further defined the structural details that define the interaction between Tankyrase and 3BP2.
“Tankyrase sits in the nexus of several known cancer pathways. These studies have helped us discern its role and have opened the door to a whole new area in how information is processed in cells that was previously obscure. We have furthered our understanding of how genes that control development often control cancer,” says Dr. Rottapel.
He adds: “This is how research happens; following unanticipated opportunities that unveil connectivity that teaches us about the general pathways that lead to human disease.”
This research was funded by the Terry Fox Research Institute, the Canadian Cancer Society Research Institute, The Princess Margaret Hospital Foundation, the Ontario Ministry of Health and Long-term Care, the Arthritis Centre for Excellence Fellowship, of T, the National Institutes of Health and the Charles H. Hood Foundation Inc., Boston.
Princess Margaret Hospital and Ontario Cancer Institute, the hospital’s research arm, have achieved an international reputation as global leaders in the fight against cancer. Princess Margaret Hospital is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital and Toronto Rehabilitation Institute. All are research hospitals affiliated with the University of Toronto. For more information, go to www.uhn.caMedia contact:
Jane Finlayson | Newswise Science News
Individual Receptors Caught at Work
19.10.2017 | Julius-Maximilians-Universität Würzburg
Rapid environmental change makes species more vulnerable to extinction
19.10.2017 | Universität Zürich
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
19.10.2017 | Materials Sciences
19.10.2017 | Materials Sciences
19.10.2017 | Physics and Astronomy